- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Skin Cancer
Volume 2013 (2013), Article ID 828329, 8 pages
Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma
1Hadassah Medical Center, Hebrew University, Kiryat Hadassah, 91120 Jerusalem, Israel
2Chaim Sheba Medical Center, Tel Hashomer, 52621 Ramat Gan, Israel
3Sackler Faculty of Medicine, Tel Aviv Medical Center, 69978 Tel Aviv, Israel
4Rambam Health Care Campus, 31096 Haifa, Israel
5Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
6Pain Therapeutics, Inc., Austin, TX 78731, USA
7Davis Medical Center, University of California, Sacramento, CA 95817, USA
Received 13 July 2012; Accepted 10 December 2012
Academic Editor: Silvia Moretti
Copyright © 2013 M. Klein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. Linos, S. M. Swetter, M. G. Cockburn, G. A. Colditz, and C. A. Clarke, “Increasing burden of melanoma in the United States,” Journal of Investigative Dermatology, vol. 129, no. 7, pp. 1666–1674, 2009.
- F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010.
- A. Ribas, K. B. Kim, L. M. Schuchter, et al., “BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma,” Journal of Clinical Oncology, vol. 29, supplement 1, abstract 8509, 2011.
- P. B. Chapman, A. Hauschild, C. Robert, et al., “Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma,” Journal of Clinical Oncology, vol. 29, supplement 1, abstract LBA4, 2011.
- D. E. Milenic, E. D. Brady, and M. W. Brechbiel, “Antibody-targeted radiation cancer therapy,” Nature Reviews Drug Discovery, vol. 3, no. 6, pp. 488–498, 2004.
- R. M. Sharkey and D. M. Goldenberg, “Perspectives on cancer therapy with radiolabeled monoclonal antibodies,” Journal of Nuclear Medicine, vol. 46, supplement 1, pp. 115S–121S, 2005.
- K. A. Cohen-Solal, S. M. Crespo-Carbone, J. Namkoong et al., “Progressive appearance of pigmentation in amelanotic melanoma lesions,” Pigment Cell Research, vol. 15, no. 4, pp. 282–289, 2002.
- K. J. Busam, K. Hester, C. Charles et al., “Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy,” Archives of Dermatology, vol. 137, no. 7, pp. 923–929, 2001.
- A. L. Rosas, J. D. Nosanchuk, M. Feldmesser, et al., “Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents,” Infection and Immunity, vol. 68, no. 5, pp. 2845–2853, 2000.
- E. Dadachova, J. D. Nosanchuk, L. Shi et al., “Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 41, pp. 14865–14870, 2004.
- E. Dadachova, E. Revskaya, M. A. Sesay et al., “Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice,” Cancer Biology and Therapy, vol. 7, no. 7, pp. 1116–1127, 2008.
- A. D. Schweitzer, V. Rakesh, E. Revskaya, A. Datta, A. Casadevall, and E. Dadachova, “Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to metastatic melanoma tumors with wide range of melanin concentrations,” Melanoma Research, vol. 17, no. 5, pp. 291–303, 2007.
- M. G. Stabin, R. B. Sparks, and E. Crowe, “OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine,” Journal of Nuclear Medicine, vol. 46, no. 6, pp. 1023–1027, 2005.
- B. W. Wessels, W. E. Bolch, L. G. Bouchet et al., “Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison,” Journal of Nuclear Medicine, vol. 45, no. 10, pp. 1725–1733, 2004.
- B. Emami, J. Lyman, A. Brown, et al., “Tolerance of normal tissue to therapeutic irradiation,” International Journal of Radiation Oncology *Biology* Physics, vol. 21, pp. 109–122, 1991.
- S. J. DeNardo, K. L. Erickson, E. Benjamin, et al., “Radioimmunotherapy for melanoma,” Clinical Research, vol. 29, pp. 434–440, 1981.
- S. M. Larson, J. A. Carrasquillo, and R. W. McGuffin, “Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience,” Radiology, vol. 155, no. 2, pp. 487–492, 1985.
- W. C. Taddei-Peters, M. V. Haspel, P. Vente et al., “Quantitation of human tumor-reactive monoclonal antibody 16.88 in the circulation and localization of 16.88 in colorectal metastatic tumor tissue using murine antiidiotypic antibodies,” Cancer Research, vol. 52, no. 9, pp. 2603–2609, 1992.